




Ingenol Mebutate

Revised: December 21, 2020.

CASRN: 75567-37-2



Drug Levels and Effects

Summary of Use during Lactation

Topical ingenol mebutate has not been studied during breastfeeding. However, after topical administration, serum concentrations were undetectable, so breastfeeding is not expected to result in exposure of the breastfed infant. If ingenol mebutate is required by the mother, it is not a reason to discontinue breastfeeding. Do not apply ingenol mebutate to the breast or nipple and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Drug Levels

Maternal Levels. According to the manufacturer, serum concentrations of ingenol mebutate and its two metabolites are below the limit of detection (<0.1 mcg/L) after topical application of approximately 1 gram of 0.05% gel to an area of 100 sq. cm.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Ingenol Mebutate

CAS Registry Number

75567-37-2

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Dermatologic Agents